Alimera Sciences (NASDAQ: ALIM) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitabiliy, dividends, valuation and risk.

Risk and Volatility

Alimera Sciences has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Insider & Institutional Ownership

43.6% of Alimera Sciences shares are owned by institutional investors. Comparatively, 27.3% of MediWound shares are owned by institutional investors. 14.0% of Alimera Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Alimera Sciences and MediWound’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Alimera Sciences $35.15 million 2.77 -$21.82 million ($0.39) -3.85
MediWound $1.84 million 79.85 -$19.19 million ($0.75) -8.93

MediWound has higher revenue, but lower earnings than Alimera Sciences. MediWound is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alimera Sciences and MediWound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alimera Sciences -68.58% N/A -35.94%
MediWound -752.78% -326.32% -48.65%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Alimera Sciences and MediWound, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alimera Sciences 0 0 3 0 3.00
MediWound 0 0 4 0 3.00

Alimera Sciences currently has a consensus target price of $4.00, suggesting a potential upside of 166.67%. MediWound has a consensus target price of $11.67, suggesting a potential upside of 74.13%. Given Alimera Sciences’ higher possible upside, research analysts clearly believe Alimera Sciences is more favorable than MediWound.

Summary

Alimera Sciences beats MediWound on 9 of the 12 factors compared between the two stocks.

About Alimera Sciences

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.